Alembic Pharma gets USFDA final approval for Travoprost eye drops

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.3%Reaction day

₹848.00

prior close

₹842.65

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.3%+0.7% vs market

Pharmaceuticals peers, median of 152sector-0.5%+0.8% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.0

15m

+0.1

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.3-0.3+0.7-0.5+0.8

Next day

+1.4+0.9+0.5+0.5+0.9

+0.5+2.3-1.8+1.0-0.5

+1.1+2.4-1.3+1.1-0.1

+0.9+1.8-0.9+1.0-0.1

+0.4+1.3-0.9+0.6-0.2

-1.3+0.4-1.8-0.2-1.1

15d

-5.5-1.1-4.4-0.3-5.3

-8.7-3.3-5.4-2.6-6.1

-8.6-0.5-8.1-2.4-6.3

-20.3-8.2-12.2-8.9-11.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alembic Pharmaceuticals has received USFDA final approval for Travoprost Ophthalmic Solution USP, 0.004%, used to reduce eye pressure in glaucoma and ocular hypertension patients. The product is therapeutically equivalent to Sandoz's Travatan Z. Per IQVIA, the US market for this drug is about US$ 61 million for the twelve months ending September 2025. Alembic now holds 232 cumulative ANDA approvals from USFDA, of which 212 are final approvals.

Likely market impact

Positive: strengthens Alembic's US generics portfolio with access to a US$ 61 million market. Revenue impact depends on launch and competition.